Wedbush Comments on Arvinas’ Q1 Earnings (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN) – Wedbush lifted their Q1 2025 earnings per share (EPS) estimates for Arvinas in a research note issued to investors on Tuesday, February 11th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.93) per share for the quarter, up from their previous estimate of ($1.57). Wedbush has a “Outperform” rating and a $57.00 price objective on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share. Wedbush also issued estimates for Arvinas’ Q2 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.75) EPS, FY2026 earnings at ($3.17) EPS, FY2027 earnings at ($3.30) EPS and FY2028 earnings at ($3.51) EPS.

ARVN has been the topic of a number of other research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Arvinas in a report on Friday, February 7th. Stifel Nicolaus lowered their target price on Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday. BTIG Research began coverage on shares of Arvinas in a report on Tuesday, December 10th. They set a “buy” rating and a $69.00 price target for the company. Guggenheim reissued a “buy” rating and set a $57.00 price target on shares of Arvinas in a research note on Wednesday. Finally, HC Wainwright restated a “buy” rating and issued a $87.00 price target on shares of Arvinas in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $59.58.

Arvinas Stock Performance

NASDAQ:ARVN opened at $17.67 on Friday. Arvinas has a 1 year low of $16.61 and a 1 year high of $53.08. The stock has a fifty day moving average price of $19.04 and a two-hundred day moving average price of $23.28. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -3.78 and a beta of 1.88.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. During the same period last year, the business earned ($2.53) earnings per share.

Institutional Trading of Arvinas

Several large investors have recently modified their holdings of ARVN. nVerses Capital LLC acquired a new position in Arvinas during the 3rd quarter worth $39,000. KBC Group NV raised its position in shares of Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after acquiring an additional 1,255 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after buying an additional 440 shares during the last quarter. Quantbot Technologies LP raised its stake in Arvinas by 147.3% during the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after acquiring an additional 2,601 shares during the period. Finally, Exchange Traded Concepts LLC lifted its holdings in Arvinas by 37.0% in the third quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock worth $164,000 after acquiring an additional 1,798 shares during the last quarter. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.